Noveltreat 0.5 mg Pre-filled Pen is a subcutaneous injectable treatment containing FDA-approved Semaglutide base (0.5 mg/0.5 ml) as its active ingredient. Semaglutide is a Glucagon-like Peptide-1 (GLP-1) receptor agonist developed to improve glycemic control in adults to help with weight reduction in people who are obese or overweight.
Sun Pharmaceutical Industries Ltd manufactures Noveltreat 0.5 mg Pen in GMP-compliant facilities. To maintain the integrity of this medication, it should be stored in a refrigerator at 2°C-8°C, but not frozen.
As a GLP-1 receptor agonist, Semaglutide binds to and activates GLP-1 receptors in the pancreas and brain. This action triggers glucose-dependent insulin secretion, suppresses glucagon release, delays gastric emptying, and promotes a sustained feeling of fullness.
The 0.5 mg dose is the first therapeutic maintenance dose, typically prescribed after patients have completed the four-week initiation period on 0.25 mg. It is used in the long-term management of weight in overweight individuals with conditions such as cardiovascular disease or Type 2 Diabetes.
The pre-filled pen is designed for once-weekly self-injection under the skin of the thigh, abdomen, or upper arm. It can be taken at any time of the day, regardless of meals. Injection sites should be rotated weekly to reduce the likelihood of skin reactions at the same location.
When using Semaglutide, gastrointestinal effects such as nausea and diarrhea can occur. These side effects are typically mild. However, seek immediate medical attention if persistent symptoms like severe abdominal pain develop, which could be a sign of Pancreatitis.
Noveltreat 0.5 mg Pre-filled Pen provides targeted metabolic benefits for adults managing Type 2 Diabetes or weight-related health conditions. Some of its benefits include:
Noveltreat 0.5 mg Pre-filled Pen is a prescription-only injectable medication. Use it strictly as instructed by your doctor or pharmacist. The general guidelines are as follows:
Noveltreat Pre-filled Pen is currently available in a single strength at Cheap Medicine Shop. However, the following effective alternatives are available:
| Wegovy 0.5 mg | $270.58/injection |
| Wegovy 0.25 mg | $270.58/injection |
| Wegovy 1 mg | $270.58/injection |
Noveltreat 0.5 mg Pre-filled Pen can cause side effects in some users, particularly during the early weeks of use. Most side effects are mild and resolve on their own as the body adapts. However, consult a healthcare professional if they persist or worsen:
Liver Disease
Noveltreat 0.5 mg should be used cautiously in patients with mild to moderate liver disease. It is not advisable in cases of severe liver impairment. A thorough medical evaluation by a doctor is essential before beginning treatment.
Kidney Impairment
This medication is generally considered suitable for patients with mild to moderate chronic kidney disease. In cases of severe renal impairment, close monitoring is required, as dehydration caused by gastrointestinal side effects can worsen kidney function. Always consult a doctor before using this medicine.
Pregnant and Breastfeeding women
Noveltreat 0.5 mg is not recommended for use during pregnancy. Animal studies have shown adverse effects on fetal development, and the safety in human pregnancies has not been established. Women should discontinue treatment and consult their doctor immediately if they become pregnant during therapy. Breastfeeding while using this medication is also not advised.
Avoid
Do not use this medicine in case of known hypersensitivity to Semaglutide or its inactive ingredients. It is contraindicated in people with a history of Medullary Thyroid Cancer (thyroid gland cancer). Avoid alcohol excess, as it may affect blood sugar levels unpredictably.
Yes, but only under medical supervision. Noveltreat 0.5 mg is often prescribed alongside other antidiabetic agents such as Metformin. If combined with insulin or Sulfonylureas, there is an increased risk of low blood sugar, so your doctor may need to reduce the dose of those medicines to maintain safe glucose levels.
This medication is not suitable for people with a known history of Medullary Thyroid Carcinoma or Multiple Endocrine Neoplasia Syndrome Type 2 (tumors of endocrine glands). It should also be avoided in patients with Type 1 Diabetes, those with a known allergy to Semaglutide, and those who are pregnant.
If you realize you have missed a dose and your next scheduled injection is still 2 or more days away, take the missed dose immediately. However, if fewer than 2 days remain until your next dose, skip the missed one entirely and continue with your usual weekly schedule.
Noveltreat 0.5 mg can be taken at any time of the day, with or without food. The most important factor is consistency. Select a day of the week that suits your routine and administer it on that same day every week.
No, Noveltreat is not recommended during pregnancy. Based on animal studies, Semaglutide has been shown to pose potential risks to fetal development. If you become pregnant while using this medication, stop the injection and consult your doctor immediately. Effective contraception is strongly advised for women of childbearing age while on this therapy.
No, on its own, Noveltreat is unlikely to cause Hypoglycemia (low blood sugar) because it stimulates insulin release only when blood glucose is elevated. However, when used in combination with insulin or Sulfonylureas, the risk of low blood sugar increases. Monitor your blood glucose regularly and discuss any concerns with your doctor.
Used pre-filled pens should be disposed of in a designated sharps container and never placed in household rubbish. Do not recap the needle. Follow your local guidelines or ask your pharmacist for safe disposal instructions for medical sharps waste.